Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 71335-1331

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 71335-1331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 01)

Chemical structure of Desvenlafaxine Succinate, showing the molecule's detailed atomic arrangement including hydroxyl, methyl, and carboxyl groups along with water of hydration.*

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 02)

A figure showing the impact of intrinsic factors such as renal impairment, hepatic impairment, and population description on the pharmacokinetics of Desvenlafaxine. It illustrates geometric mean ratios with 90% confidence intervals for Cmax and AUC parameters across categories like mild, moderate, severe renal and hepatic impairment, ESRD, gender, and age groups relative to a reference.*

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 03)

A pharmacokinetics chart titled 'Effect of Other Drugs on Desvenlafaxine Pharmacokinetics,' showing geometric mean ratios with 90% confidence intervals for Cmax and AUC influenced by the CYP3A4 inhibitor Ketoconazole. The x-axis represents change relative to reference, ranging from 0.50 to 2.0.*

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 04)

Figure 3 presents a chart illustrating the effects of Desvenlafaxine on the pharmacokinetics of other drugs. It shows geometric mean ratios (with 90% confidence intervals) of pharmacokinetic parameters such as Cmax and AUC for various interacting drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole at different Desvenlafaxine doses (50 mg, 100 mg, 400 mg). The chart displays changes relative to reference values on a horizontal scale from 0.5 to 2.5.*

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 05)

A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5).' The x-axis represents time to relapse in days from randomization, ranging from 0 to 200 days. The y-axis shows the estimated proportion of patients with relapse, expressed as a percentage from 0% to 50%. Two plotted lines compare Desvenlafaxine extended-release tablets 50 mg and placebo, with the placebo line showing a higher relapse proportion over time.*

FDA Label Image

Image (E33fdabd C42d 47bf Af0a 1b6d3637f519 06)

A Kaplan-Meier curve depicting time to relapse (days from randomization) versus estimated proportion of patients with relapse (%) comparing Desvenlafaxine extended-release tablets and placebo groups. The x-axis represents time to relapse in days, and the y-axis shows the proportion of patients experiencing relapse percentage over time.*

FDA Label Image

Label (Lbl713351331)

Label for Desvenlafaxine ER 100 mg tablet, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Pristiq 100 mg tablet from Lupin Limited. It includes storage instructions at 20°-25°C and a warning to keep drugs out of children's reach. The package contains 30 tablets, NDC 71335-1331.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.